Vaccinex, INC 10-Q quarterly reports

Vaccinex reported its Q3 2024 financial results, highlighting a net loss and ongoing concerns about its ability to continue as a going concern, while also announcing positive clinical trial data for its Alzheimer's drug candidate.

Vaccinex, Inc. released its second quarter 2024 financial results, detailing ongoing clinical trial progress and financial updates, while also noting concerns about its ability to continue as a going concern.

Vaccinex, a clinical-stage biotech company, reported a net loss of $3.9 million for the first quarter of 2024, while also addressing Nasdaq compliance issues and securing new funding.